Skip to main content

Published locations for Alirocumab reduces both type 1 and 2 MIs

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Alirocumab reduces both type 1 and 2 MIs

User login

  • Reset your password
  • /content/alirocumab-reduces-both-type-1-and-2-mis
  • /clinicianreviews/article/198529/lipid-disorders/alirocumab-reduces-both-type-1-and-2-mis
  • /familypracticenews/article/198529/lipid-disorders/alirocumab-reduces-both-type-1-and-2-mis
  • /fedprac/article/198529/lipid-disorders/alirocumab-reduces-both-type-1-and-2-mis
  • /internalmedicinenews/article/198529/lipid-disorders/alirocumab-reduces-both-type-1-and-2-mis
  • /clinicalendocrinologynews/article/198529/lipid-disorders/alirocumab-reduces-both-type-1-and-2-mis
  • /ecardiologynews/article/198529/lipid-disorders/alirocumab-reduces-both-type-1-and-2-mis
  • /cardiology/article/198529/lipid-disorders/alirocumab-reduces-both-type-1-and-2-mis
  • /endocrinology/article/198529/lipid-disorders/alirocumab-reduces-both-type-1-and-2-mis
  • /internalmedicine/article/198529/lipid-disorders/alirocumab-reduces-both-type-1-and-2-mis
  • /familymedicine/article/198529/lipid-disorders/alirocumab-reduces-both-type-1-and-2-mis
  • /chestphysician/article/198529/lipid-disorders/alirocumab-reduces-both-type-1-and-2-mis